Immunodominant PstS1 antigen of is a potent biological response modifier for the treatment of bladder cancer-1

<p><b>Copyright information:</b></p><p>Taken from "Immunodominant PstS1 antigen of is a potent biological response modifier for the treatment of bladder cancer"</p><p>BMC Cancer 2004;4():86-86.</p><p>Published online 26 Nov 2004</p><p>PMCID:PMC544192.</p><p>Copyright © 2004 Sänger et al; licensee BioMed Central Ltd.</p>oxicity (A), IFN-γ-production (B) and proliferation (C) of PBMC were measured after 2, 5 and 7 days of stimulation. Cytotoxicity assay. 4-hour chromium release assay against T-24 bladder tumor cells. Effector-target cell ratio of 40:1. IFN-γ release measured by ELISA from culture media of PBMC. PBMC proliferation measured by overnight H-Thymidine incorporation assay (1 μCi/2 × 10cells). For A and B one representative experiment out of 3 is shown (mean ± SD), for C a composite of seven independent experiments is shown (mean ± SEM). For PHA-stimulation one out of two experiments is shown (mean ± SD) . n.d. = not detectabl